--- title: "MIRA Pharmaceuticals Reports Positive Phase 1 Ketamir-2 Results" type: "News" locale: "en" url: "https://longbridge.com/en/news/286319406.md" description: "MIRA Pharmaceuticals, Inc. reported positive Phase 1 results for Ketamir-2, an oral NMDA receptor modulator, in a study involving 57 healthy volunteers. The trial showed no serious adverse events and mild side effects, with a higher incidence of adverse events in the placebo group. The company plans to submit for Phase 2a FDA evaluation for chemotherapy-induced peripheral neuropathy. Analysts rate MIRA stock as a Buy with an $8.00 price target. MIRA focuses on developing novel therapeutics for pain management, with a current market cap of $42.86M." datetime: "2026-05-13T21:14:25.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286319406.md) - [en](https://longbridge.com/en/news/286319406.md) - [zh-HK](https://longbridge.com/zh-HK/news/286319406.md) --- # MIRA Pharmaceuticals Reports Positive Phase 1 Ketamir-2 Results ### Claim 55% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks MIRA Pharmaceuticals, Inc. ( (MIRA) ) has issued an update. MIRA Pharmaceuticals, Inc. reported positive unblinded results from a completed Phase 1 clinical trial of Ketamir-2, its oral NMDA receptor modulator, in 57 healthy volunteers across single and multiple ascending dose cohorts. The randomized, double-blind, placebo-controlled study found no serious adverse events or dose-limiting toxicities, predominantly mild side effects, and a higher incidence of adverse events in the placebo group than in Ketamir-2 recipients. Pharmacokinetic data showed rapid oral absorption, dose-proportional exposure, and half-lives for Ketamir-2 and its active metabolite nor-Ketamir-2 consistent with potential once-daily dosing, with no major differences between first and fifth day administration. The company is preparing a Phase 2a submission to the U.S. Food and Drug Administration to evaluate Ketamir-2 in chemotherapy-induced peripheral neuropathy, supported by preclinical models where it outperformed ketamine and standard neuropathic pain drugs, and by a U.S. Drug Enforcement Administration determination that it is not a controlled substance. The most recent analyst rating on (MIRA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on MIRA Pharmaceuticals, Inc. stock, see the MIRA Stock Forecast page. **More about MIRA Pharmaceuticals, Inc.** MIRA Pharmaceuticals, Inc. operates in the biopharmaceutical industry, focusing on the development of novel, proprietary small-molecule therapeutics. Its pipeline includes Ketamir-2, a selective oral NMDA receptor modulator being advanced for neuropathic pain conditions, including chemotherapy-induced peripheral neuropathy, targeting significant unmet medical needs in pain management. **Average Trading Volume:** 153,554 **Technical Sentiment Signal:** Hold **Current Market Cap:** $42.86M ### Related Stocks - [MIRA.US](https://longbridge.com/en/quote/MIRA.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) ## Related News & Research - [Relay drug shows early promise against rare blood vessel diseases](https://longbridge.com/en/news/287094432.md) - [Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study | DWTX Stock News](https://longbridge.com/en/news/286772955.md) - [Eton Pharmaceuticals Adds Another 2026 Launch As It Secures U.S. Rights To IMPAVIDO](https://longbridge.com/en/news/287025596.md) - [NeOnc Advances Glioma Programs and Strengthens Financial Position](https://longbridge.com/en/news/286826865.md) - [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md)